![](/sites/default/files/styles/medium/public/oembed_thumbnails/6ajy71pamhUqJCDHEbIPqOWaeLtC-eZOlJJtPHeDTiQ.jpg?itok=BcPJtiiV)
Adam Schechter became chief executive officer of Labcorp (NYSE: LH) in November 2019, and chairman in May 2020. Prior to that, he was named lead independent director in January 2019 after serving on the board since 2013. Schechter joined Labcorp after a long and distinguished career at Merck, where he most recently served as executive vice president and president of global human health, and was a member of the executive committee. At Merck, among other accomplishments, Schechter focused on ensuring that Merck's medicines and vaccines were available to people around the world; led a large global organization across the spectrum of commercial operations; transformed Merck's commercial model; and led the integration of Merck and Schering-Plough. He held a number of professional, managerial, and executive roles with the company. Prior to his most recent role as president of global human health, Merck's global pharmaceuticals and vaccines business, Schechter served as president of the global pharmaceutical business. Before that, he led Merck's U.S. pharmaceutical business. He began his career with Merck as a sales representative. Schechter is also the board chair for Water.org, chair of the Corporate Advisory Council of the National Alliance for Hispanic Health, and executive advisor to the Healthy Americas Foundation. He holds a Bachelor of Arts in Biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from the university in 2021.